Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2024.06.042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Artemisinin-Quinidine Combination for Suppressing Ventricular Tachyarrhythmia in an Ex Vivo Model of Brugada Syndrome.
J Korean Med Sci
January 2025
Division of Cardiology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Background: The ionic mechanism underlying Brugada syndrome (BrS) arises from an imbalance in transient outward current flow between the epicardium and endocardium. Previous studies report that artemisinin, originally derived from a Chinese herb for antimalarial use, inhibits the Ito current in canines. In a prior study, we showed the antiarrhythmic effects of artemisinin in BrS wedge preparation models.
View Article and Find Full Text PDFManagement of Muscle Cramps in Patients With Cirrhosis: A Systematic Review of Randomised Controlled Trials.
Aliment Pharmacol Ther
January 2025
Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
Background: Muscle cramps are common in patients with cirrhosis. Despite their prevalence and impact on health-related quality of life, there are no widely used clinical practice guidelines for management of muscle cramps in cirrhosis. The aim of this review was to critically evaluate current evidence regarding treatment of muscle cramps in cirrhosis.
View Article and Find Full Text PDFA Review of Dextromethorphan-Quinidine for the Treatment of Agitation in Dementia.
Prim Care Companion CNS Disord
November 2024
Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
To provide an updated summary of the literature on dextromethorphan quinidine for the treatment of agitation in dementia. PubMed, Medline, APA PsycINFO, Embase, and Cochrane Collaboration were searched from inception to January 7, 2024 using the keywords , , and . The search was limited to the English language and human subjects.
View Article and Find Full Text PDFDiscovery of Potent and Selective Blockers Targeting the Epilepsy-Associated K1.1 Channel.
J Med Chem
November 2024
State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Gain-of-function (GOF) mutations of the sodium-activated potassium channel K1.1 (Slack, Slo2.2, or K4.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!